We use cookies to personalise the web experience for you. By using www.helgilibrary.com, you agree to our use of cookies.
Some cookies are also used by Google Analytics, which anonymously tracks visitors and helps us to analyse how users use our website. Read more

Roche Czech Republic

Pharmaceutical > Czech Republic > Roche Czech Republic
Change Company
Roche Czech Republic

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was

Read more »
Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was the fifth-largest pharma company worldwide. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.

Buy all financials of Roche Czech Republic

from $199 /month

Buy annual subscriptions for all our products.

summary Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

income statement

Sales CZK mil
Gross Profit CZK mil
EBIT CZK mil
Net Profit CZK mil
ROE %
EBIT Margin %
Net Margin %
Employees
            4,866 5,073 5,011 4,869 4,934    
            733 680 620 634 770    
            127 138 83.1 69.0 183    
            87.4 101 50.5 38.7 135    
            10.1% 10.5% 4.85% 3.57% 11.5%    
            2.61% 2.72% 1.66% 1.42% 3.71%    
            1.80% 1.99% 1.01% 0.794% 2.73%    
            201 226 220 216 216    

balance sheet

            2,008 2,473 2,238 2,344 2,245    
            342 386 329 354 338    
            1,658 2,085 1,971 1,988 1,905    
            914 1,015 1,065 1,104 1,239    
            1,094 1,458 1,173 1,240 1,006    
            0.000 0.949 1.46 0.000 0.000    
            1,089 1,451 1,163 1,231 978    
            0.140 1.67 -0.002 0.737 0.867    
            0.036 0.416 < -0.001 0.137 0.230    
...           8.98% 1.19% 0.316% -2.24% 0.681%    

cash flow

            47.6 -232 65.2 159 127    
            -80.8 -158 -65.5 -159 -127    
            33.1 390 0.000 0.000 0.000    
            -0.181 0.195 -0.286 -0.134 0.104    

Download Data
income statement Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

income statement

Sales CZK mil
Cost of Goods & Services CZK mil
Gross Profit CZK mil
Staff Cost CZK mil
Other Cost CZK mil
EBITDA CZK mil
Depreciation CZK mil
EBIT CZK mil
Financing Cost CZK mil
Extraordinary Cost CZK mil
Pre-Tax Profit CZK mil
Tax CZK mil
Minorities CZK mil
Net Profit CZK mil
            4,866 5,073 5,011 4,869 4,934    
            4,132 4,393 4,392 4,235 4,164    
            733 680 620 634 770    
            327 338 329 345 373    
            172 88.8 82.6 85.0 68.6    
            234 254 208 204 328    
            107 116 125 135 145    
            127 138 83.1 69.0 183    
            1.49 2.72 0.669 -1.69 1.48    
            0.000 0.000 0.000 0.000 0.000    
            125 135 82.4 70.7 182    
            37.9 34.2 31.9 32.0 46.9    
            0.000 0.000 0.000 0.000 0.000    
            87.4 101 50.5 38.7 135    

growth rates

...           10.6% 4.27% -1.23% -2.83% 1.33%    
...           8.61% -14.5% -3.47% 4.38% 2.78%    
...           -18.5% 8.45% -18.2% -1.49% 60.6%    
...           -31.7% 8.91% -39.8% -16.9% 165%    
...           -28.7% 8.03% -39.1% -14.2% 157%    
...           -34.3% 15.7% -50.1% -23.3% 248%    

ratios

            10.1% 10.5% 4.85% 3.57% 11.5%    
...           9.06% 8.06% 4.01% 3.25% 8.93%    
            15.1% 13.4% 12.4% 13.0% 15.6%    
            4.81% 5.00% 4.14% 4.20% 6.66%    
            2.61% 2.72% 1.66% 1.42% 3.71%    
            1.80% 1.99% 1.01% 0.794% 2.73%    
...           8.98% 1.19% 0.316% -2.24% 0.681%    
            0.140 1.67 -0.002 0.737 0.867    

Download Data
balance sheet Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

balance sheet

            342 386 329 354 338    
            342 386 329 354 338    
            0.015 0.000 0.000 0.000 0.000    
            1,658 2,085 1,971 1,988 1,905    
            1,093 1,409 767 872 775    
            548 635 983 1,087 1,108    
            0.467 0.662 0.376 0.242 0.346    
            2,008 2,473 2,238 2,344 2,245    
            914 1,015 1,065 1,104 1,239    
            0.000 0.000 0.000 0.000 0.000    
            1,094 1,458 1,173 1,240 1,006    
            0.000 0.949 1.46 0.000 0.000    
            0.000 0.000 0.000 0.000 0.000    
            0.000 0.949 1.46 0.000 0.000    
            1,089 1,451 1,163 1,231 978    
            33.1 423 0.000 151 285    
            967 936 1,056 953 562    
            4.75 6.38 7.65 9.24 27.6    
            2,008 2,473 2,238 2,344 2,245    

growth rates

...           10.5% 23.2% -9.52% 4.74% -4.23%    
...           10.6% 11.1% 4.97% 3.63% 12.2%    
...           -5,065% 1,193% -100% -40,192% 88.9%    
...           ... 1,177% -100% ... 88.9%    

ratios

            33.1 423 0.000 151 285    
            32.7 422 -0.376 151 285    
            675 1,108 694 1,007 1,321    
            1,016 1,495 1,023 1,361 1,659    
            0.036 0.416 < -0.001 0.137 0.230    
...           8.98% 1.19% 0.316% -2.24% 0.681%    

Download Data
cash flow Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

cash flow

            87.4 101 50.5 38.7 135    
            107 116 125 135 145    
...           -39.2 -14.5 -524 297 161    
...           -108 -434 414 -312 -314    
            47.6 -232 65.2 159 127    
            -107 -163 -77.6 -165 -143    
            25.8 5.21 12.1 5.53 16.2    
            -80.8 -158 -65.5 -159 -127    
...           33.1 390 -423 151 134    
            33.1 390 0.000 0.000 0.000    
            -0.181 0.195 -0.286 -0.134 0.104    

ratios

            41.1 45.7 71.6 81.5 81.9    
            96.5 117 63.7 75.2 67.9    
            85.4 77.7 87.8 82.1 49.3    
            52.3 85.0 47.6 74.5 101    
            194 217 175 174 280    
            -33.3 -390 -0.286 -0.134 0.104    

Download Data
other data Unit
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

other data

            4.57% 4.52% 2.14% 1.69% 5.88%    
            15.1% 13.4% 12.4% 13.0% 15.6%    
            201 226 220 216 216    
            7,117 6,520 7,054 6,805 7,362    
            135,638 124,598 124,765 133,116 144,043    
            6.90% 6.85% 6.68% 7.19% 7.86%    
            30.2% 25.2% 38.8% 45.3% 25.8%    
            2.19% 3.22% 1.55% 3.38% 2.90%    
... ... ... ... ... ... ... ... ... ... ...    
... ... ... ... ... ... ... ... ... ... ...    
            4,518 4,729 4,686 4,568 4,606    
            347 344 326 301 328    
...           3,563 3,721 3,630 3,533 3,806   ...
...           955 1,009 1,082 1,035 1,128   ...

Download Data
Roche Czech Republic at a Glance

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's

Read more »

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was the fifth-largest pharma company worldwide. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.

This report offers a summary of the company's performance in 2003-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Roche Czech Republic in Numbers

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's

Read more »

Roche, s.r.o. is a Czech Republic-based subsidiary of the Swiss global health-care company F. Hoffmann-La Roche Ltd (or Roche Holding AG as it is listed on the SIX Swiss Exchange). Roche operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The Company headquarters are located in Basel and the Company has some 26 manufacturing sites worldwide. Roche's revenues during fiscal year 2013 were CHF 46.8 bil and the Company was the fifth-largest pharma company worldwide. Descendants of the founding Hoffmann and Oeri families own slightly over half of the bearer shares with voting rights (a pool of family shareholders 45%, and Maja Oeri a further 5% apart), with Swiss pharma firm Novartis owning a further third of its shares.

This excel file offers a summary of the company's performance in 2003-2012. You will find here all the key numbers from the company's balance sheet, income statement and cash flow on the annual, in the local currency as well as in USD

Skoda Auto invested total of CZK 118 mil in 2015, down 10.8% when compared to the previous year. Historically, company's investments reached an all time high of CZK 165 mil in 2012 and an all time low of CZK 77.6 mil in 2011.

Read more »

Skoda Auto invested total of CZK 118 mil in 2015, down 10.8% when compared to the previous year. Historically, company's investments reached an all time high of CZK 165 mil in 2012 and an all time low of CZK 77.6 mil in 2011.

When compared to total sales, investments reached 2.16% in 2015, down from 3.02% seen in the previous year. This is compared to 2.60% seen on average in the last five years.

As far as Roche Czech Republic's peers are concerned, CZK 0.695 mil and 0.115% at Amgen Czech Republic invested CZK 0.695 mil, or 0.115% of its sales in 2015. on 2015 numbers.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

Roche Czech Republic's net debt reached CZK 660 mil and accounted for 0.557 of equity at the end of 2015. The ratio is up 16.7% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time

Read more »

Roche Czech Republic's net debt reached CZK 660 mil and accounted for 0.557 of equity at the end of 2015. The ratio is up 16.7% when compared to the previous year.

Historically, the firm’s net debt to equity reached an all time high of 1.13 in 2004 and an all time low of -0.100 in 2003.

When compared to EBITDA, net debt amounted to 3.15x at the end of the year. The ratio reached an all time high of 4.29 in 2007 and an all time low of -0.170 in 2003.

As far as Roche Czech Republic's peers are concerned, Bayer Czech Republic posted net debt to equity of 0.608x and 0.890x when compared to EBITDA at the end of 2015. Amgen Czech Republic ended the year 2015 with a net debt at 0.387x of equity and 1.53x when compared to its EBITDA while Amgen Czech Republic had net debt at 0.387x of equity and 1.53x to EBITDA at the end of the year.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

Roche Czech Republic's total assets reached CZK 2,548 mil at the end of 2015, up 8.14% when compared to the previous year.

Current assets amounted to CZK 2,228 mil, or 87.4% of total assets while cash reached CZK 0.046 mil at the end of 2015.

Read more »

Roche Czech Republic's total assets reached CZK 2,548 mil at the end of 2015, up 8.14% when compared to the previous year.

Current assets amounted to CZK 2,228 mil, or 87.4% of total assets while cash reached CZK 0.046 mil at the end of 2015.

On the other hand, total debt reached CZK 660 mil at the year-end, or 87.4% of total assets while firm's equity amounted to CZK 1,185 mil. As a result, net debt reached CZK 660 mil at the end of 2015 and accounted for 55.7% of equity.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

Roche Czech Republic made a net profit of CZK 51.0 mil under revenues of CZK 5,445 mil in 2015, down -46.3% and 24.8%, respectively, when compared to the last year. This translates into a net margin of 0.936%.

Historically, the

Read more »

Roche Czech Republic made a net profit of CZK 51.0 mil under revenues of CZK 5,445 mil in 2015, down -46.3% and 24.8%, respectively, when compared to the last year. This translates into a net margin of 0.936%.

Historically, the firm’s net profit reached an all time high of CZK 135 mil in 2013 and an all time low of CZK 3.04 mil in 2003. Since 2010, the firm's net profit has increased -49.6% or -12.8% a year on average.

On the operating level, EBITDA reached CZK 209 mil, up -21.0% when compared to the previous year. Over the last five years, company's EBITDA has grown -3.77% a year on average.

As far as Roche Czech Republic's peers are concerned, Bayer Czech Republic posted net and EBITDA margin of 2.89% and 3.93%, respectively in 2015 and Amgen Czech Republic generated margins of 5.93% and 7.66%.

You can see all the company’s data at Roche Czech Republic Profile, or you can download a report on the company in the report section.

See all charts of the company »